APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antisense and RNAi Therapeutics Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antisense and RNAi Therapeutics Drug Market Analysis and Forecast 2026-2032

21 December 2025190 pages

Choose your research edition.

Industry ResearchAntisense and RNAi Therapeutics Drug Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Antisense and RNAi Therapeutics Drug Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Antisense and RNAi Therapeutics Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antisense and RNAi Therapeutics Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Antisense and RNAi Therapeutics Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Antisense and RNAi Therapeutics Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Antisense and RNAi Therapeutics Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antisense and RNAi Therapeutics Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antisense and RNAi Therapeutics Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antisense and RNAi Therapeutics Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Antisense and RNAi Therapeutics Drug include Biogen, Sarepta Therapeutics, Kastle therapeutics, Jazz Pharmaceuticals, Dynavax Technologies, Bausch & Lomb, Alnylam Pharmaceuticals and Akcea Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Antisense and RNAi Therapeutics Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antisense and RNAi Therapeutics Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Antisense and RNAi Therapeutics Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antisense and RNAi Therapeutics Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antisense and RNAi Therapeutics Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Antisense and RNAi Therapeutics Drug revenue, projected growth trends, production technology, application and end-user industry.

Antisense and RNAi Therapeutics Drug Segment by Company

Biogen

Sarepta Therapeutics

Kastle therapeutics

Jazz Pharmaceuticals

Dynavax Technologies

Bausch & Lomb

Alnylam Pharmaceuticals

Akcea Therapeutics

Antisense and RNAi Therapeutics Drug Segment by Type

Antisense Oligonucleotide

Aptamer

Other

Antisense and RNAi Therapeutics Drug Segment by Application

ATTR

Hepatic VOD

Neuromuscular Diseases

Other

Antisense and RNAi Therapeutics Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense and RNAi Therapeutics Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antisense and RNAi Therapeutics Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense and RNAi Therapeutics Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Antisense and RNAi Therapeutics Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Antisense and RNAi Therapeutics Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antisense and RNAi Therapeutics Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antisense and RNAi Therapeutics Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Antisense Oligonucleotide Major Player Table 3. Aptamer Major Player Table 4. Other Major Player Table 5. Global Antisense and RNAi Therapeutics Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. ATTR Major Player Table 7. Hepatic VOD Major Player Table 8. Neuromuscular Diseases Major Player Table 9. Other Major Player Table 10. Antisense and RNAi Therapeutics Drug Industry Trends Table 11. Antisense and RNAi Therapeutics Drug Industry Drivers Table 12. Antisense and RNAi Therapeutics Drug Industry Opportunities and Challenges Table 13. Antisense and RNAi Therapeutics Drug Industry Restraints Table 14. Global Antisense and RNAi Therapeutics Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Antisense and RNAi Therapeutics Drug Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Antisense and RNAi Therapeutics Drug Market Share by Region (2021-2026) Table 17. Global Antisense and RNAi Therapeutics Drug Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Antisense and RNAi Therapeutics Drug Market Share by Region (2027-2032) Table 19. Global Antisense and RNAi Therapeutics Drug Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Antisense and RNAi Therapeutics Drug Revenue Market Share by Players (2021-2026) Table 21. Global Antisense and RNAi Therapeutics Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Antisense and RNAi Therapeutics Drug Key Players Headquarters & Area Served Table 23. Global Antisense and RNAi Therapeutics Drug Players, Product Type & Application Table 24. Global Antisense and RNAi Therapeutics Drug Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Antisense and RNAi Therapeutics Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Antisense and RNAi Therapeutics Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Antisense and RNAi Therapeutics Drug Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Antisense and RNAi Therapeutics Drug Revenue Market Share by Type (2021-2026) Table 31. Global Antisense and RNAi Therapeutics Drug Revenue Market Share by Type (2027-2032) Table 32. Global Antisense and RNAi Therapeutics Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Antisense and RNAi Therapeutics Drug Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Antisense and RNAi Therapeutics Drug Revenue Market Share by Application (2021-2026) Table 36. Global Antisense and RNAi Therapeutics Drug Revenue Market Share by Application (2027-2032) Table 37. Biogen Company Information Table 38. Biogen Business Overview Table 39. Biogen Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Biogen Antisense and RNAi Therapeutics Drug Product Portfolio Table 41. Biogen Recent Development Table 42. Sarepta Therapeutics Company Information Table 43. Sarepta Therapeutics Business Overview Table 44. Sarepta Therapeutics Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Sarepta Therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio Table 46. Sarepta Therapeutics Recent Development Table 47. Kastle therapeutics Company Information Table 48. Kastle therapeutics Business Overview Table 49. Kastle therapeutics Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Kastle therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio Table 51. Kastle therapeutics Recent Development Table 52. Jazz Pharmaceuticals Company Information Table 53. Jazz Pharmaceuticals Business Overview Table 54. Jazz Pharmaceuticals Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Jazz Pharmaceuticals Antisense and RNAi Therapeutics Drug Product Portfolio Table 56. Jazz Pharmaceuticals Recent Development Table 57. Dynavax Technologies Company Information Table 58. Dynavax Technologies Business Overview Table 59. Dynavax Technologies Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Dynavax Technologies Antisense and RNAi Therapeutics Drug Product Portfolio Table 61. Dynavax Technologies Recent Development Table 62. Bausch & Lomb Company Information Table 63. Bausch & Lomb Business Overview Table 64. Bausch & Lomb Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Bausch & Lomb Antisense and RNAi Therapeutics Drug Product Portfolio Table 66. Bausch & Lomb Recent Development Table 67. Alnylam Pharmaceuticals Company Information Table 68. Alnylam Pharmaceuticals Business Overview Table 69. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Drug Product Portfolio Table 71. Alnylam Pharmaceuticals Recent Development Table 72. Akcea Therapeutics Company Information Table 73. Akcea Therapeutics Business Overview Table 74. Akcea Therapeutics Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Akcea Therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio Table 76. Akcea Therapeutics Recent Development Table 77. North America Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2026) & (US$ Million) Table 78. North America Antisense and RNAi Therapeutics Drug Revenue by Type (2027-2032) & (US$ Million) Table 79. North America Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2026) & (US$ Million) Table 80. North America Antisense and RNAi Therapeutics Drug Revenue by Application (2027-2032) & (US$ Million) Table 81. North America Antisense and RNAi Therapeutics Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. North America Antisense and RNAi Therapeutics Drug Revenue by Country (2021-2026) & (US$ Million) Table 83. North America Antisense and RNAi Therapeutics Drug Revenue by Country (US$ Million) & (2027-2032) Table 84. Europe Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2026) & (US$ Million) Table 85. Europe Antisense and RNAi Therapeutics Drug Revenue by Type (2027-2032) & (US$ Million) Table 86. Europe Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2026) & (US$ Million) Table 87. Europe Antisense and RNAi Therapeutics Drug Revenue by Application (2027-2032) & (US$ Million) Table 88. Europe Antisense and RNAi Therapeutics Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. Europe Antisense and RNAi Therapeutics Drug Revenue by Country (2021-2026) & (US$ Million) Table 90. Europe Antisense and RNAi Therapeutics Drug Revenue by Country (US$ Million) & (2027-2032) Table 91. China Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2026) & (US$ Million) Table 92. China Antisense and RNAi Therapeutics Drug Revenue by Type (2027-2032) & (US$ Million) Table 93. China Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2026) & (US$ Million) Table 94. China Antisense and RNAi Therapeutics Drug Revenue by Application (2027-2032) & (US$ Million) Table 95. Asia Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2026) & (US$ Million) Table 96. Asia Antisense and RNAi Therapeutics Drug Revenue by Type (2027-2032) & (US$ Million) Table 97. Asia Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2026) & (US$ Million) Table 98. Asia Antisense and RNAi Therapeutics Drug Revenue by Application (2027-2032) & (US$ Million) Table 99. Asia Antisense and RNAi Therapeutics Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Asia Antisense and RNAi Therapeutics Drug Revenue by Region (US$ Million) & (2021-2026) Table 101. Asia Antisense and RNAi Therapeutics Drug Revenue by Region (US$ Million) & (2027-2032) Table 102. SAMEA Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2026) & (US$ Million) Table 103. SAMEA Antisense and RNAi Therapeutics Drug Revenue by Type (2027-2032) & (US$ Million) Table 104. SAMEA Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2026) & (US$ Million) Table 105. SAMEA Antisense and RNAi Therapeutics Drug Revenue by Application (2027-2032) & (US$ Million) Table 106. SAMEA Antisense and RNAi Therapeutics Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. SAMEA Antisense and RNAi Therapeutics Drug Revenue by Country (2021-2026) & (US$ Million) Table 108. SAMEA Antisense and RNAi Therapeutics Drug Revenue by Country (US$ Million) & (2027-2032) Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Antisense and RNAi Therapeutics Drug Image Figure 2. Global Antisense and RNAi Therapeutics Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antisense and RNAi Therapeutics Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Antisense Oligonucleotide Image Figure 5. Aptamer Image Figure 6. Other Image Figure 7. Global Antisense and RNAi Therapeutics Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Antisense and RNAi Therapeutics Drug Market Size Share 2021 VS 2025 VS 2032 Figure 9. ATTR Image Figure 10. Hepatic VOD Image Figure 11. Neuromuscular Diseases Image Figure 12. Other Image Figure 13. Global Antisense and RNAi Therapeutics Drug Market Size (US$ Million) & (2021-2032) Figure 14. Global Antisense and RNAi Therapeutics Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Antisense and RNAi Therapeutics Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Antisense and RNAi Therapeutics Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Antisense and RNAi Therapeutics Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Antisense and RNAi Therapeutics Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Antisense and RNAi Therapeutics Drug Revenue Market Share by Type (2021-2032) Figure 21. Global Antisense and RNAi Therapeutics Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Antisense and RNAi Therapeutics Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Antisense and RNAi Therapeutics Drug Revenue Market Share by Application (2021-2032) Figure 24. North America Antisense and RNAi Therapeutics Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Antisense and RNAi Therapeutics Drug Revenue Share by Type (2021-2032) Figure 26. North America Antisense and RNAi Therapeutics Drug Revenue Share by Application (2021-2032) Figure 27. North America Antisense and RNAi Therapeutics Drug Revenue Share by Country (2021-2032) Figure 28. United States Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Antisense and RNAi Therapeutics Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Antisense and RNAi Therapeutics Drug Revenue Share by Type (2021-2032) Figure 33. Europe Antisense and RNAi Therapeutics Drug Revenue Share by Application (2021-2032) Figure 34. Europe Antisense and RNAi Therapeutics Drug Revenue Share by Country (2021-2032) Figure 35. Germany Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Antisense and RNAi Therapeutics Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Antisense and RNAi Therapeutics Drug Revenue Share by Type (2021-2032) Figure 45. China Antisense and RNAi Therapeutics Drug Revenue Share by Application (2021-2032) Figure 46. Asia Antisense and RNAi Therapeutics Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Antisense and RNAi Therapeutics Drug Revenue Share by Type (2021-2032) Figure 48. Asia Antisense and RNAi Therapeutics Drug Revenue Share by Application (2021-2032) Figure 49. Asia Antisense and RNAi Therapeutics Drug Revenue Share by Region (2021-2032) Figure 50. Japan Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Antisense and RNAi Therapeutics Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Antisense and RNAi Therapeutics Drug Revenue Share by Type (2021-2032) Figure 58. SAMEA Antisense and RNAi Therapeutics Drug Revenue Share by Application (2021-2032) Figure 59. SAMEA Antisense and RNAi Therapeutics Drug Revenue Share by Country (2021-2032) Figure 60. Brazil Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Antisense and RNAi Therapeutics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Antisense Oligonucleotide
  • Aptamer
  • Other
Applications
  • ATTR
  • Hepatic VOD
  • Neuromuscular Diseases
  • Other
Companies covered
  • Biogen
  • Sarepta Therapeutics
  • Kastle therapeutics
  • Jazz Pharmaceuticals
  • Dynavax Technologies
  • Bausch & Lomb
  • Alnylam Pharmaceuticals
  • Akcea Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antisense and RNAi Therapeutics Drug Market by Type
  3. 1.2.1 Global Antisense and RNAi Therapeutics Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Antisense Oligonucleotide
  5. 1.2.3 Aptamer
  6. 1.2.4 Other
  7. 1.3 Antisense and RNAi Therapeutics Drug Market by Application
  8. 1.3.1 Global Antisense and RNAi Therapeutics Drug Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 ATTR
  10. 1.3.3 Hepatic VOD
  11. 1.3.4 Neuromuscular Diseases
  12. 1.3.5 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Antisense and RNAi Therapeutics Drug Market Dynamics
  1. 2.1 Antisense and RNAi Therapeutics Drug Industry Trends
  2. 2.2 Antisense and RNAi Therapeutics Drug Industry Drivers
  3. 2.3 Antisense and RNAi Therapeutics Drug Industry Opportunities and Challenges
  4. 2.4 Antisense and RNAi Therapeutics Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Antisense and RNAi Therapeutics Drug Market Perspective (2021-2032)
  2. 3.2 Global Antisense and RNAi Therapeutics Drug Growth Trends by Region
  3. 3.2.1 Global Antisense and RNAi Therapeutics Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antisense and RNAi Therapeutics Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Antisense and RNAi Therapeutics Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Antisense and RNAi Therapeutics Drug Revenue by Players
  2. 4.1.1 Global Antisense and RNAi Therapeutics Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Antisense and RNAi Therapeutics Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Antisense and RNAi Therapeutics Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antisense and RNAi Therapeutics Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Antisense and RNAi Therapeutics Drug Key Players Headquarters & Area Served
  7. 4.4 Global Antisense and RNAi Therapeutics Drug Players, Product Type & Application
  8. 4.5 Global Antisense and RNAi Therapeutics Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Antisense and RNAi Therapeutics Drug Market CR5 and HHI
  11. 4.6.3 2025 Antisense and RNAi Therapeutics Drug Tier 1, Tier 2, and Tier 3
5 Antisense and RNAi Therapeutics Drug Market Size by Type
  1. 5.1 Global Antisense and RNAi Therapeutics Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2032)
  3. 5.3 Global Antisense and RNAi Therapeutics Drug Revenue Market Share by Type (2021-2032)
6 Antisense and RNAi Therapeutics Drug Market Size by Application
  1. 6.1 Global Antisense and RNAi Therapeutics Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2032)
  3. 6.3 Global Antisense and RNAi Therapeutics Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Biogen
  2. 7.1.1 Biogen Company Information
  3. 7.1.2 Biogen Business Overview
  4. 7.1.3 Biogen Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Biogen Antisense and RNAi Therapeutics Drug Product Portfolio
  6. 7.1.5 Biogen Recent Developments
  7. 7.2 Sarepta Therapeutics
  8. 7.2.1 Sarepta Therapeutics Company Information
  9. 7.2.2 Sarepta Therapeutics Business Overview
  10. 7.2.3 Sarepta Therapeutics Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sarepta Therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio
  12. 7.2.5 Sarepta Therapeutics Recent Developments
  13. 7.3 Kastle therapeutics
  14. 7.3.1 Kastle therapeutics Company Information
  15. 7.3.2 Kastle therapeutics Business Overview
  16. 7.3.3 Kastle therapeutics Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Kastle therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio
  18. 7.3.5 Kastle therapeutics Recent Developments
  19. 7.4 Jazz Pharmaceuticals
  20. 7.4.1 Jazz Pharmaceuticals Company Information
  21. 7.4.2 Jazz Pharmaceuticals Business Overview
  22. 7.4.3 Jazz Pharmaceuticals Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Jazz Pharmaceuticals Antisense and RNAi Therapeutics Drug Product Portfolio
  24. 7.4.5 Jazz Pharmaceuticals Recent Developments
  25. 7.5 Dynavax Technologies
  26. 7.5.1 Dynavax Technologies Company Information
  27. 7.5.2 Dynavax Technologies Business Overview
  28. 7.5.3 Dynavax Technologies Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Dynavax Technologies Antisense and RNAi Therapeutics Drug Product Portfolio
  30. 7.5.5 Dynavax Technologies Recent Developments
  31. 7.6 Bausch & Lomb
  32. 7.6.1 Bausch & Lomb Company Information
  33. 7.6.2 Bausch & Lomb Business Overview
  34. 7.6.3 Bausch & Lomb Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bausch & Lomb Antisense and RNAi Therapeutics Drug Product Portfolio
  36. 7.6.5 Bausch & Lomb Recent Developments
  37. 7.7 Alnylam Pharmaceuticals
  38. 7.7.1 Alnylam Pharmaceuticals Company Information
  39. 7.7.2 Alnylam Pharmaceuticals Business Overview
  40. 7.7.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Drug Product Portfolio
  42. 7.7.5 Alnylam Pharmaceuticals Recent Developments
  43. 7.8 Akcea Therapeutics
  44. 7.8.1 Akcea Therapeutics Company Information
  45. 7.8.2 Akcea Therapeutics Business Overview
  46. 7.8.3 Akcea Therapeutics Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Akcea Therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio
  48. 7.8.5 Akcea Therapeutics Recent Developments
8 North America
  1. 8.1 North America Antisense and RNAi Therapeutics Drug Revenue (2021-2032)
  2. 8.2 North America Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Antisense and RNAi Therapeutics Drug Revenue by Type (2027-2032)
  5. 8.3 North America Antisense and RNAi Therapeutics Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Antisense and RNAi Therapeutics Drug Revenue by Application (2027-2032)
  9. 8.5 North America Antisense and RNAi Therapeutics Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Antisense and RNAi Therapeutics Drug Revenue by Country
  11. 8.6.1 North America Antisense and RNAi Therapeutics Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Antisense and RNAi Therapeutics Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Antisense and RNAi Therapeutics Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Antisense and RNAi Therapeutics Drug Revenue (2021-2032)
  2. 9.2 Europe Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Antisense and RNAi Therapeutics Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Antisense and RNAi Therapeutics Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Antisense and RNAi Therapeutics Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Antisense and RNAi Therapeutics Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Antisense and RNAi Therapeutics Drug Revenue by Country
  11. 9.6.1 Europe Antisense and RNAi Therapeutics Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Antisense and RNAi Therapeutics Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Antisense and RNAi Therapeutics Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Antisense and RNAi Therapeutics Drug Revenue (2021-2032)
  2. 10.2 China Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Antisense and RNAi Therapeutics Drug Revenue by Type (2027-2032)
  5. 10.3 China Antisense and RNAi Therapeutics Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Antisense and RNAi Therapeutics Drug Revenue by Application (2027-2032)
  9. 10.5 China Antisense and RNAi Therapeutics Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antisense and RNAi Therapeutics Drug Revenue (2021-2032)
  2. 11.2 Asia Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Antisense and RNAi Therapeutics Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Antisense and RNAi Therapeutics Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Antisense and RNAi Therapeutics Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Antisense and RNAi Therapeutics Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Antisense and RNAi Therapeutics Drug Revenue by Country
  11. 11.6.1 Asia Antisense and RNAi Therapeutics Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Antisense and RNAi Therapeutics Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Antisense and RNAi Therapeutics Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antisense and RNAi Therapeutics Drug Revenue (2021-2032)
  2. 12.2 SAMEA Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Antisense and RNAi Therapeutics Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Antisense and RNAi Therapeutics Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Antisense and RNAi Therapeutics Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Antisense and RNAi Therapeutics Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Antisense and RNAi Therapeutics Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Antisense and RNAi Therapeutics Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Antisense and RNAi Therapeutics Drug Revenue by Country
  11. 12.6.1 SAMEA Antisense and RNAi Therapeutics Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Antisense and RNAi Therapeutics Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Antisense and RNAi Therapeutics Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst